Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free ...
Kisqali has been FDA-approved with an aromatase inhibitor as postsurgical treatment for some with early breast cancer at a ...
Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...
The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It ...
Will taking Kisqali with Femara increase my risk of certain side effects? It’s possible that taking Kisqali with Femara (letrozole) may increase the risk of certain side effects. In studies of ...
The FDA approved ribociclib (Kisqali) for adjuvant treatment of high-risk, hormone receptor-positive, HER2-negative early breast cancer. The FDA approved ribociclib (Kisqali) with an aromatase ...
This new indication also applies to Kisqali Femara Co-Pack (ribociclib with letrozole). The approval was based on data from the phase 3 NATALEE trial (NCT03701334), which enrolled 5101 adults with ...
Medpage Today on MSN4d
FDA Expands Approval of Ribociclib to Early Breast CancerThe drug joins abemaciclib (Verzenio) as approved CDK4/6 inhibitors in this setting, but the broader indication for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback